Q2 FY2026 Performance Highlights

  • Revenue at ₹12,208m, grew 4.6% YoY
  • Absolute gross margin at ₹7,056m, grew 14.6% YoY
  • Gross margin improved to 57.8%, up 500bps YoY
  • EBITDA grew 25.4% YoY to ₹2,316m, EBITDA margin at 19.0%, grew 320bps YoY
  • Other Regulated Markets revenue at $44m, delivered strong growth of 16% YoY
  • Operational PAT at ₹1,403m, Grew 84.3% YoY
  • Operational EPS at ₹15.2
  • Reported PAT at ₹1,315m

Bangalore : Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q2FY26) and half year (H1FY26) ended September 30, 2025.

Financial Highlights (In ₹ m)

Particulars     Q2FY26  Q2FY25   YoY    Q1FY26   QoQ   H1FY26   H1FY25   YoY

Revenue           12,208    11,669    4.6%  11,197     9.0%   23,406   22,213     5.4%

Gross Margin  7,056    6,159  14.6%  6,755     4.5%  13,810   12,204  13.2%

Gross

Margin %         57.8%   52.8%    500     60.3%    -250    59.0%      54.9%   410

                                                           bps                      bps                                       bps

EBITDA                   2,316   1,846  25.4%  2,181  6.2%   4,496         3,746   20.0%

EBITDA %              19.0%   15.8%  320   19.5%  -50     19.2%       16.9%    230

                                                             bps                  bps                                    bps

Operational

PAT*                  1,403    761         84.3%   1,140  23.1%  2,543        1,392            82.6%

Operational

EPS (₹)               15.2    8.3        83.8%    12.4    23.0%   27.6        15.1         82.2%

*Operational PAT = Reported PAT excluding exceptional items

FY25 Numbers presented reflect the restated financials post the demerger of Softgel business Badree Komandur, MD & Group CEO, commented on the performance and said, “Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the Other Regulated Markets. Our focus on profitability enabled the gross margin growth of 15% YoY, and EBITDA growth of 25% YoY. Operational PAT stood at ₹1,403m, up 84% YoY, with EPS rising to ₹15.2 for the quarter. Net debt reduced sequentially by ₹469m despite currency headwinds and ongoing capex investments, reaffirming our strong financial discipline and focus on balance sheet health. This performance demonstrates our consistent execution as we continue to invest in sustainable, long-term growth.”